VSIR and neoplasm: Recently, the effects of a VISTA mAb (HMBD-002) inhibiting VSIG3 suppression of T cell activity, have been shown to be potentiated by a distinct shift in the TME to a pro-inflammatory phenotype, thus inhibiting tumour growth in vivo in preclinical syngeneic and humanised murine models of colorectal, lung, and breast cancer [114].